Literature DB >> 10438864

Adenovirus-mediated expression of a ribozyme to c-myb mRNA inhibits smooth muscle cell proliferation and neointima formation in vivo.

D G Macejak1, H Lin, S Webb, J Chase, K Jensen, T C Jarvis, J M Leiden, L Couture.   

Abstract

Smooth muscle cell (SMC) proliferation is an important component of restenosis in response to injury after balloon angioplasty. Inhibition of proliferation in vivo can limit neointima hyperplasia in animal models of restenosis. Ribozymes against c-myb mRNA have been shown to be effective inhibitors of SMC proliferation in vitro. The effectiveness of adenovirus as a gene therapy vector in animal models of restenosis is well documented. In order to test the utility of ribozymes to inhibit SMC proliferation by a gene therapy approach, recombinant adenovirus expressing ribozymes against c-myb mRNA was generated and tested both in vitro and in vivo. This adenovirus ribozyme vector is shown to inhibit SMC proliferation in culture and neointima formation in a rat carotid artery balloon injury model of restenosis.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10438864      PMCID： PMC104301     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  20 in total

1.  Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo.

Authors:  M Simons; E R Edelman; J L DeKeyser; R Langer; R D Rosenberg
Journal:  Nature       Date:  1992-09-03       Impact factor: 49.962

Review 2.  A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies.

Authors:  J S Forrester; M Fishbein; R Helfant; J Fagin
Journal:  J Am Coll Cardiol       Date:  1991-03-01       Impact factor: 24.094

3.  Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia.

Authors:  R Morishita; G H Gibbons; K E Ellison; M Nakajima; L Zhang; Y Kaneda; T Ogihara; V J Dzau
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

4.  Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa.

Authors:  A S Lewin; K A Drenser; W W Hauswirth; S Nishikawa; D Yasumura; J G Flannery; M M LaVail
Journal:  Nat Med       Date:  1998-08       Impact factor: 53.440

5.  Development and analysis of recombinant adenoviruses for gene therapy of cystic fibrosis.

Authors:  D P Rich; L A Couture; L M Cardoza; V M Guiggio; D Armentano; P C Espino; K Hehir; M J Welsh; A E Smith; R J Gregory
Journal:  Hum Gene Ther       Date:  1993-08       Impact factor: 5.695

6.  Methylphosphate cap structure increases the stability of 7SK, B2 and U6 small RNAs in Xenopus oocytes.

Authors:  G Shumyatsky; D Wright; R Reddy
Journal:  Nucleic Acids Res       Date:  1993-10-11       Impact factor: 16.971

7.  Gene therapy for vascular smooth muscle cell proliferation after arterial injury.

Authors:  T Ohno; D Gordon; H San; V J Pompili; M J Imperiale; G J Nabel; E G Nabel
Journal:  Science       Date:  1994-08-05       Impact factor: 47.728

8.  In vivo suppression of injury-induced vascular smooth muscle cell accumulation using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene.

Authors:  R J Guzman; E A Hirschowitz; S L Brody; R G Crystal; S E Epstein; T Finkel
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-25       Impact factor: 11.205

9.  Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product.

Authors:  M W Chang; E Barr; J Seltzer; Y Q Jiang; G J Nabel; E G Nabel; M S Parmacek; J M Leiden
Journal:  Science       Date:  1995-01-27       Impact factor: 47.728

Review 10.  Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia.

Authors:  M W Liu; G S Roubin; S B King
Journal:  Circulation       Date:  1989-06       Impact factor: 29.690
View more
  4 in total

Review 1.  Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biological function.

Authors:  L M Khachigian
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

2.  Ribozyme rescue of photoreceptor cells in P23H transgenic rats: long-term survival and late-stage therapy.

Authors:  M M LaVail; D Yasumura; M T Matthes; K A Drenser; J G Flannery; A S Lewin; W W Hauswirth
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

Review 3.  The cell cycle: a critical therapeutic target to prevent vascular proliferative disease.

Authors:  Thierry Charron; Nafiseh Nili; Bradley H Strauss
Journal:  Can J Cardiol       Date:  2006-02       Impact factor: 5.223

4.  RelB-p50 NF-kappa B complexes are selectively induced by cytomegalovirus immediate-early protein 1: differential regulation of Bcl-x(L) promoter activity by NF-kappa B family members.

Authors:  H Y Jiang; Constantinos Petrovas; Gail E Sonenshein
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.